27994747|t|Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes
27994747|a|GPR142 has been identified as a potential glucose-stimulated insulin secretion (GSIS) target for the treatment of type 2 diabetes mellitus (T2DM). A class of triazole GPR142 agonists was discovered through a high throughput screen. The lead compound 4 suffered from poor metabolic stability and poor solubility. Lead optimization strategies to improve potency, efficacy, metabolic stability, and solubility are described. This optimization led to compound 20e, which showed significant reduction of glucose excursion in wild-type but not in GPR142 deficient mice in an oral glucose tolerance test (oGTT) study. These studies provide strong evidence that reduction of glucose excursion through treatment with 20e is GPR142 -mediated, and GPR142 agonists could be used as a potential treatment for type 2 diabetes.
27994747	0	9	Discovery	T052	C1880355
27994747	14	26	Optimization	T052	C2698650
27994747	32	37	Novel	T080	C0205314
27994747	38	53	Triazole Series	T109,T121	C1689939
27994747	57	63	GPR142	T116,T192	C1570380
27994747	64	72	Agonists	T121	C0243192
27994747	81	90	Treatment	T169	C1522326
27994747	94	109	Type 2 Diabetes	T047	C0011860
27994747	110	116	GPR142	T116,T192	C1570380
27994747	142	151	potential	T080	C3245505
27994747	152	188	glucose-stimulated insulin secretion	T043	C2245393
27994747	190	194	GSIS	T043	C2245393
27994747	196	202	target	T169	C1521840
27994747	211	220	treatment	T169	C1522326
27994747	224	248	type 2 diabetes mellitus	T047	C0011860
27994747	250	254	T2DM	T047	C0011860
27994747	259	276	class of triazole	T109,T121	C1689939
27994747	277	283	GPR142	T116,T192	C1570380
27994747	284	292	agonists	T121	C0243192
27994747	297	307	discovered	T052	C1880355
27994747	318	340	high throughput screen	T060	C0872187
27994747	346	361	lead compound 4	T121	C1254351
27994747	376	380	poor	T080	C0542537
27994747	381	390	metabolic	T169	C0311400
27994747	391	400	stability	T080	C0205360
27994747	405	409	poor	T080	C0542537
27994747	410	420	solubility	T080	C0037628
27994747	427	439	optimization	T052	C2698650
27994747	454	461	improve	T033	C0184511
27994747	462	469	potency	T080	C0205556
27994747	471	479	efficacy	T080	C1280519
27994747	481	490	metabolic	T169	C0311400
27994747	491	500	stability	T080	C0205360
27994747	506	516	solubility	T080	C0037628
27994747	537	549	optimization	T052	C2698650
27994747	557	569	compound 20e	T121	C1254351
27994747	596	605	reduction	T080	C0392756
27994747	609	626	glucose excursion	T034	C0428548
27994747	630	639	wild-type	T015	C1520150
27994747	651	657	GPR142	T116,T192	C1723023
27994747	658	667	deficient	T169	C0011155
27994747	668	672	mice	T015	C0025929
27994747	679	706	oral glucose tolerance test	T060	C0029161
27994747	708	712	oGTT	T060	C0029161
27994747	727	734	studies	T062	C2603343
27994747	764	773	reduction	T080	C0392756
27994747	777	794	glucose excursion	T034	C0428548
27994747	803	812	treatment	T169	C1522326
27994747	818	821	20e	T121	C1254351
27994747	825	831	GPR142	T116,T192	C1723023
27994747	847	853	GPR142	T116,T192	C1723023
27994747	854	862	agonists	T121	C0243192
27994747	882	891	potential	T080	C3245505
27994747	892	901	treatment	T169	C1522326
27994747	906	921	type 2 diabetes	T047	C0011860